SCHEMBL1863248

SCHEMBL1863248

N#Cc1c[nH]c(C(=O)O)n1

nearest known ligand 0.39

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.39
AHR P35869 1/20 0.34
CAMKK2 Q96RR4 2/20 0.33
LMNA P02545 1/20 0.31
CGAS Q8N884 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19868327 0.78 CREBBP (0.35) AHRCAMKK2
SCHEMBL15418827 0.74 PIN1 (0.37) PIN1LMNA
SCHEMBL8680461 0.71 CYP3A4 (0.41) LMNA
Water SCHEMBL29953274 0.71 NOTUM (0.39) PIN1LMNACGAS
SCHEMBL15436508 0.70 KMT2A (0.46) LMNA
SCHEMBL87944 0.70 ALOX15 (0.41) PIN1LMNACGAS
SCHEMBL15418828 0.70
SCHEMBL16050347 0.68
SCHEMBL4335085 0.68
SCHEMBL780237 0.68

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12469929-B2 Separator, electrical apparatus containing such separator, and preparation method thereof CONTEMPORARY AMPEREX TECHNOLOGY (HONG KONG) LIMITED (CN) 2025-11-11 US claimed
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION THE JOHNS HOPKINS UNIVERSITY 2021-09-23 US claimed
EP-3208269-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2021-09-15 EP claimed
EP-3813890-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION The Johns Hopkins University (US) 2021-05-05 EP claimed
EP-3208269-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica N.V. (BE) 2017-08-23 EP claimed
EP-1807077-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-11-23 EP claimed
US-8497376-B2 4-Cyano-1H-imidazole-2-carboxylic acid [2-cyclohex-1-enyl-4-(2,6-dioxo-piperidin-4-yl)-phenyl]-amide; tyrosine kinase inhibitor; autoimmune diseases, antiinflammatory, anticarcinogenic agent JANSSEN PHARMACEUTICA N.V. (BE) 2013-07-30 US claimed
US-7790724-B2 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2010-09-07 US claimed
EP-2215079-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica N.V. (BE) 2010-08-11 EP claimed
US-7705042-B2 Class of arylamide compounds useful as inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2010-04-27 US claimed
EP-1807407-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP claimed
EP-1807077-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-18 EP claimed
WO-2007048088-A2 METHOD OF INHIBITING FLT3 KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-26 WO claimed
US-20060258666-A1 c-fms kinase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2006-11-16 US claimed
US-20060189623-A1 Inhibitors of c-fms kinase ILLIG CARL R 2006-08-24 US claimed
US-20060148812-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA N.V. (BE) 2006-07-06 US claimed
US-20060100201-A1 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-11 US claimed
WO-2006047277-A2 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
WO-2006047504-A1 AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-04 WO claimed
US-5750692-A Synthesis of 3-deazapurines ISIS PHARMACEUTICALS, INC. (US) 1998-05-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060189623-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES PIN1 2417/4885AHR 1843/4885CAMKK2 73/4885
US-20060100201-A1 Inhibitors of c-fms kinase MUSK, FLT3, FES PIN1 2273/4885AHR 1652/4885CAMKK2 70/4885
US-20060148812-A1 Inhibitors of c-fms kinase MUSK, TYK2, FES PIN1 2417/4885AHR 1843/4885CAMKK2 73/4885
US-20210290784-A1 POSITRON EMISSION TOMOGRAPHY (PET) RADIOTRACERS FOR IMAGING MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR (CSF1R) IN NEUROINFLAMMATION CSF1R, CSF3R, CMKLR1 PIN1 4669/4885AHR 2147/4885CAMKK2 3922/4885
US-20060258666-A1 c-fms kinase inhibitors FLT3, FES, FER PIN1 1677/4885AHR 2238/4885CAMKK2 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.